Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFS202A in advanced solid tumor patients with pre-cachexia or cachexia
NCT06898255Phase 1Recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GFS202A in cancer cachexia (6 arms), sponsored by GenFleet Therapeutics. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events and Incidence of Dose-Limiting Toxicities. Started Apr 2025; status: recruiting.
02
Drugs
GFS202A
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT06898255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898255.